Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

How Multiple Sclerosis Damages a Brain Long Before Symptoms Appear

By the time patients start seeking care for multiple sclerosis (MS), the disease has already been damaging their brain for years. But until recently, scientists didn’t understand which brain cells were being targeted or when the injury began. Now, by analyzing

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

By the time patients start seeking care for multiple sclerosis (MS), the disease has already been damaging their brain for years. But until recently, scientists didn’t understand which brain cells were being targeted or when the injury began.

Now, by analyzing thousands of proteins found in the blood, scientists at the University of California, San Francisco (UCSF), have created what they view as the clearest picture yet of when the disease attacks the myelin sheath that covers the nerve fibers. It shows that the immune system begins attacking the brain even earlier than previously had been thought.

The study “Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis,” published in Nature Medicine, measured debris from these attacks in a person’s blood, along with the signals that coordinate the immune system to go on the attack. It lays out, for the first time, the sequence of events that eventually lead to the disease.

The discovery could lead to new ways to diagnose multiple sclerosis—and possibly one day prevent it, noted the scientists. MS first attacks the fatty myelin sheath, and a year later, it’s possible to see the breakdown of nerve fibers themselves.

Immune signaling proteins

Among the many immune signaling proteins that were elevated in the early stage of the disease, one protein stood out: IL-3. It plays an important role in this early phase when the central nervous system is suffering significant damage, but the patient doesn’t yet feel it. IL-3 is known for recruiting immune cells to the brain and spinal cord, where they attack nerve cells.

“We think our work opens numerous opportunities for diagnosing, monitoring, and possibility treating MS,” said Ahmed Abdelhak, MD, assistant professor of neurology at UCSF, and the first and co-lead author of the paper. “It could be a gamechanger for how we understand and manage this disease.”

Researchers analyzed more than 5,000 proteins in blood samples from 134 people with MS, both before and after their diagnosis. These samples were provided by the U.S. Department of Defense Serum Repository, which stores samples from armed service members when they apply to join the military. The samples are then available for study decades afterwards, by which time some of the people may have gone on to develop MS.

Seven years before a person’s diagnosis, they saw a spike in a protein called MOG, which stands for myelin oligodendrocyte glycoprotein and indicates damage to the insulation around the wires of the nervous system. A year after the MOG spike appeared, they saw a spike in another protein called neurofilament light chain, which indicates damage to the wires themselves.

During this time, IL-3 and some related proteins that orchestrate an immune reaction appeared in the blood. The team identified about 50 proteins that herald future disease, and they have submitted a patent application for a diagnostic blood test using the top 21 of them.

According to Ari Green, MD, chief of the division of neuroimmunology and glial biology in the UCSF department of neurology and senior author of the paper, points out the study offers the hope of prevention and it gives a deeper understanding of what leads to the development of symptoms in MS.

“We now know that MS starts way earlier than the clinical onset, creating the real possibility that we could someday prevent MS—or at least use our understanding to protect people from further injury.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →